Newly-developed thyroid hormone receptor beta (THR-β)-selective agonist Resmetirom nicely suppressed human liver fibrosis in 25% of MASH patients, while it caused severe diarrhea and nausea in 10% of patients (Harrison et al, 2024). The gene discussed is THRB; the disease is metabolic dysfunction-associated steatohepatitis.